Радионуклидная тераностика злокачественных образований

В данном обзоре представлена основная информация, касающаяся относительно нового перспективного направления, получившего название «тераностика», рассматриваются его главные принципы. Особое внимание уделено изучению подходов при выборе наиболее целесообразных для решения соответствующих диагностических и терапевтических задач радиоизотопов. Также представлены основные направления работы с моноклональными антителами и их использования в радионуклидной тераностике.

персонализированная медицина, тераностика, радиоизотопы, моноклональные антитела, рецепторы эпидермального фактора роста, злокачественные образования

1. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Ann. Rev. Genomics Hum. Genet. 2011; 12: 217–44.

2. Дедов И.И., Тюльпаков А.Н., Чехонин В.П., Баклаушев В.П., Арчаков А.И., Мошковский С.А. Персонифицированная медицина: современное состояние и перспективы. Вестник РАМН. 2012; 12: 4–12.

3. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat. Med. 2012; 18: 312–26.

4. Hoggatt J. Personalized medicine trends in molecular diagnostics: exponential growth expected in the next ten years. Mol. Diagn. Ther. 2011; 15: 53–5.

5. Hodgson D.R., Wellings R., Harbron C. Practical perspectives of personalized healthcare in oncology. N. Biothechnol. 2012; 29 (Suppl. 6): 656–64.

6. Thomson A. Why do therapeutic drug monitoring. Pharm. J. 2004; 273: 153–5.

7. Idée J.M., Louguet S., Ballet S., Сorot C. Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med. Surg. 2013; 3 (Suppl. 6): 292–7.

8. Kelkar S.S., Reineke T.M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 2011; 22: 1879–903.

9. Полянский О.Л., Лебеденко Е.Н., Деев С.М. ERBB онкогены – мишени моноклональных антител. Биохимия. 2012; 77 (Приложение 3): 289–311.

10. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D. et al. Phase II trial of pertuzumab and trastuzumab in patients with human growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010; 28: 1138–44.

11. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J. Clin. Oncol. 2010; 28: 1124–30.

12. Boussen H., Cristofanilli M., Zaks T., DeSilvio M., Salazar V., Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J. Clin. Oncol. 2010; 28: 3248–55.

13. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R. et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbBpositive breast cancer. J. Clin. Oncol. 2010; 28: 1301–7.

14. Laverman P., Sosabowski J.K., Boerman O.C., Oyen W.J. Radiolabelled peptides for oncological diagnosis. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (Suppl. 1): 78–92.

15. Лишманов Ю.Б., Чернов В.И. Национальное руководство по радионуклидной диагностике. Том 1. Томск: STT; 2010.

16. Фомин Д.К., Тарарухина О.Б., Назаров А.А., Борисова О.А. Варианты системной лучевой терапии в лечении метастатического поражения скелета. Вестник рентгенологии и радиологии. 2012; 6: 30–4.

17. Denoye D., Pouliot N. Radionuclide theranostics in cancer. J. Mol. Imaging Dynam. 2013; 4 (Suppl. 1): 1–2.

18. Baum R.P., Kulkarni H.R. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the bad berka experience. Theranostics. 2012; 2: 437–47.

19. Hicks R.J. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010; 10: 83–91.

20. Jandl T., Revskaya E., Jiang Z., Bryan R.A., Casadevall A., Dadachova E. Complement dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy. 2013; 5: 357–64.

21. Beer A.J., Haubner R., Sarbia M., Goebel M., Luderschmidt S., Grosu A.L. et al. Positron emission tomography using [18F] GalactoRGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res. 2006; 12: 3942–9.

22. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S. et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002; 62: 6146–51.

23. Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy. Immunotherapy. 2011; 3 (Suppl. 3): 349–70.

24. Кодина Г.Е., Красикова Р.Н. Методы получения радиофармацевтических препаратов и радионуклидных генераторов для ядерной медицины. М.: МЭИ; 2014.

25. Cutler C.S., Hennkens H.M., Sisay N., Huclier-Markai S., Jurisson S.S. Radiometals for combined imaging and therapy. Chem. Rev. 2013; 113 (Suppl. 2): 858–83.

26. Lin F.I., Iagaru A. Current concepts and future directions in radioimmunotherapy. Cur. Drug Discov. Technol. 2010; 7 (Suppl. 4): 253–62.

27. Farrokhi S., Ravanbod M.R., Amiri S., Nabipour I., Assadi M. Radioimmunotherapy-based treatment of cancer. Iran J. Nucl. Med. 2012; 20 (Suppl. 1): 45–53.

28. Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies. Sci. World J. 2014; 14: 1–10.

29. Wilken J.A., Maihle N.J. Primary trastuzumab resistance: new tricks for an old drug. Ann. NY Acad. Sci. 2010; 1210: 53–65.

30. Chen K.T., Lee T.W., Lo J.M. In vivo examination of (188) Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Nucl. Med. Biol. 2009; 36 (Suppl. 4): 355–61.

31. Rasaneh S., Rajabi H., Babaei M.H., Daha F.J. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl. Med. Biol. 2010; 37 (Suppl. 8): 949–55.

32. Song H., Hobbs R.F., Vajravelu R., Huso D.L., Esaias C., Apostolidis C. et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y. Cancer Res. 2009; 69 (Suppl. 23): 8941–8.

33. Song H., Shahverdi K., Huso D.L., Esaias C., Fox J., Liedy A. et al. 213Bi (alpha-emitter) – antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008; 68 (Suppl. 10): 3873–80.

34. Abbas N., Heyerdahl H., Brul and О.S., Borrebak J., Nesland J., Dahle J. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab. EJNMMI Research. 2011; 1: 1–12.

35. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med. Oncol. 2012; 29: 2481–91.

36. Sihver W., Pietzsch J., Krause M., Baumann M., Steinbach J., Pietzsch H.-J. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals. 2014; 7: 311–38.

37. Rades D., Nadrowitz R., Buchmann I., Hunold P., Noack F., Schild S.E. et al. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther. Onkol. 2010; 186: 458–62.

38. Heskamp S., Boerman O.C., Molkenboer-Kuenen J.D., Oyen W.J., van der Graaf W.T., van Laarhoven H.W. et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulinlike growth factor 1 receptor antibodies. Int. J. Cancer. 2013; 133 (Suppl. 2): 307–14.

39. Kinuya S., Yokoyama K., Koshida K., Mori H., Shiba K., Watanabe N. et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur. J. Nucl. Med. Mol. Imaging. 2004; 31: 981–5.

40. Salaun P.Y., Bodet-Milin C., Frampas E., Oudoux A., Saї-Maurel C., Faivre-Chauvet A. et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer. 2010; 116: 1053–8.

41. Kraeber-Bodere F., Bodet-Milin C., Niaudet C., Saї-Maurel C., Moreau A., Faivre-Chauvet A. et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antingiogenic therapy in carcinoembryonic antigenexpressing medullary thyroid cancer xenograft. J. Nucl. Med. 2010; 51: 624–31.

42. Баклаушев В.П., Павлов К.А., Чехонин В.П. Моноклональные антитела в диагностике низкодифференцированных лимфом. Биомедицинская химия. 2009; 2: 140–54.

43. Kitson S.L., Cuccurullo V., Moody T.S., Mansi L. Radionuclide antibody-conjugates, a targeted therapy towards cancer. Current Radiopharm. 2013; 6 (Suppl. 2): 57–71.

44. Boerman O.C., van Schaijk F.G., Oyen W.J.G., Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 2003; 44 (Suppl. 3): 400–11.

45. Семенова А.И. Основные принципы системной терапии Her-2-позитивного рака молочной железы. Практическая онкология. 2010; 11 (4): 239–46.

46. Pastuskovas C.V., Mundo E.E., Williams S.P., Nayak T.K., Ho J., Ulufatu S. et al. Effects of antiVEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 2012; 11 (Suppl. 3): 752–62.